Zanubrutinib-Obinutuzumab could double PFS in patients with follicular lymphoma

Time : 23rd of June 2022 01:59:13 PM

The overall response rate in patients who received Zanubrutinib-Obinutuzumab (ZO) was 68.3%, compared to 45.8% in those who received only Obinutuzumab (O), as per a study. Also, the complete response rate was 37.2% with ZO therapy than 19.4% with only O therapy. The median progression-free survival with ZO therapy was 27.4 months compared to 11.2 months with only O therapy.

  European Hematology Association


zanubrutinib, obinutuzumab, follicular lymphoma

Recent Posts

FDA warns against compounding semaglutide
2nd of June 2023 04:00:38 PM

Alzheimer's could raise the risk of epilepsy
2nd of June 2023 03:35:09 PM

Exercise could improve pain tolerance
2nd of June 2023 02:43:04 PM

New treatment for REM sleep behaviour disorder
31st of May 2023 01:00:19 PM